Mainz Biomed Announces 1-For-10 Stock Split; Expected To Begin Trading On The Split-Adjusted Basis At Market Open On December 3, 2024, Upon Nasdaq's Approval
Mainz Biomed Announces 1-For-10 Stock Split; Expected To Begin Trading On The Split-Adjusted Basis At Market Open On December 3, 2024, Upon Nasdaq's Approval
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024.
Mainz Biomed N.V.（納斯達克:MYNZ）（"Mainz Biomed" 或 "公司"）是一家專門從事癌症早期檢測的分子遺傳學診斷公司，今日宣佈將其已發行和流通股份進行1比40的逆向股票拆分。逆向股票拆分經公司董事會授權，根據2024年11月20日召開的特別股東大會獲得的股東授權批准。
The reverse stock split is expected to become effective on December 3, 2024 (the "Effective Date"), and the Company's ordinary shares are expected to begin trading on the split-adjusted basis on the Nasdaq under the Company's existing trading symbol "MYNZ" at market open on December 3, 2024, upon Nasdaq's approval. The new CUSIP number for the Company's ordinary shares following the reverse stock split will be N5436L119.
反向拆股預計將於2024年12月3日（"生效日期"）生效，公司的普通股預計將在2024年12月3日市場開盤時，在納斯達克以公司現有交易標的"MYNZ"的拆股調整基礎上開始交易，前提是獲得納斯達克的批准。反向拆股後，公司普通股的新CUSIP號碼將爲N5436L119。
The reverse stock split is intended to increase the market price per share of its common stock to comply with the continued listing standards of the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) and to make investments in the Company more attractive to investors by increasing the trading price of the Company's ordinary shares on such market.
反向拆股旨在提高公司普通股的每股市場價格，以符合納斯達克資本市場持續上市標準，根據納斯達克上市規則5550(a)(2)，並通過提高公司普通股在該市場的交易價格，使公司對投資者的投資更具吸引力。
譯文內容由第三人軟體翻譯。
